Nature Communications (Jun 2022)
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
- R. C. Coombes,
- P. D. Badman,
- J. P. Lozano-Kuehne,
- X. Liu,
- I. R. Macpherson,
- I. Zubairi,
- R. D. Baird,
- N. Rosenfeld,
- J. Garcia-Corbacho,
- N. Cresti,
- R. Plummer,
- A. Armstrong,
- R. Allerton,
- D. Landers,
- H. Nicholas,
- L. McLellan,
- A. Lim,
- F. Mouliere,
- O. E. Pardo,
- M. J. Seckl
Affiliations
- R. C. Coombes
- Department of Surgery and Cancer, Imperial College London
- P. D. Badman
- Department of Surgery and Cancer, Imperial College London
- J. P. Lozano-Kuehne
- Department of Surgery and Cancer, Imperial College London
- X. Liu
- Department of Surgery and Cancer, Imperial College London
- I. R. Macpherson
- Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre
- I. Zubairi
- Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre
- R. D. Baird
- Medical Oncology, Addenbrooke’s Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre
- N. Rosenfeld
- Medical Oncology, Addenbrooke’s Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre
- J. Garcia-Corbacho
- Medical Oncology, Addenbrooke’s Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre
- N. Cresti
- Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital
- R. Plummer
- Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital
- A. Armstrong
- Breast Research Office, The Christie NHS Foundation Trust, Christie Hospital
- R. Allerton
- C8 Admin Offices, Russell’s Hall Hospital
- D. Landers
- Astrazeneca
- H. Nicholas
- Department of Surgery and Cancer, Imperial College London
- L. McLellan
- ECMC Programme Office, Research and Innovation, Cancer Research UK
- A. Lim
- Department of Metabolism, Digestion and Reproduction, Imperial College London
- F. Mouliere
- Medical Oncology, Addenbrooke’s Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre
- O. E. Pardo
- Department of Surgery and Cancer, Imperial College London
- M. J. Seckl
- Department of Surgery and Cancer, Imperial College London
- DOI
- https://doi.org/10.1038/s41467-022-30666-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
FGFR-1 upregulation has been associated with endocrine therapy resistance in breast cancer patients. Here the authors report the results of a phase IIa study to assess the safety and efficacy of AZD454, an inhibitor of FGFR-1, 2 and 3 receptor tyrosine kinases, in combination with anastrozole or letrozole, in estrogen receptor positive breast cancer patients.
